

## Synthesis of Novel Spin Labeled Daunomycin Derivatives


Shu Jia ZHANG\*, Yan Guang WANG\*, Ju Biao LI

Department of Chemistry, Zhejiang University, Hangzhou 310027

**Abstract:** Three spin labeled daunomycin derivatives **2-4** were synthesized and their biological activities were tested against mouse leukemia L1210 and human liver cancer BEL-7402 cells *in vitro*.

**Keywords:** Spin labeled daunomycin derivatives, antitumor activity, synthesis.

The anthracycline antibiotics daunomycin **1** is clinically useful antineoplastic agents, with a broad spectrum of activity. However, it is hampered by a number of undesirable side effects, especially serious cardiotoxicity and this stimulated the search for new anthracyclines with improved pharmacological profiles<sup>1-3</sup>. In our group, nitroxyl radicals were first introduced to daunomycin and two spin labeled daunomycin derivatives have been reported recently<sup>4</sup>. Now we reported other three new spin labeled daunomycin derivatives **2-4**. Their antitumor activity against mouse leukemia L1210 and human liver cancer BEL-7402 cells were evaluated *in vitro*.



Compounds **2** and **3** were synthesized by condensing daunomycin **1** with **5** (molar ratio **1:5**=1:1.2) in the solvent of dichloromethane with DCC and DMAP as catalysts at room temperature for 18 h in the yields of 64.1% and 10.1%, respectively. Compound **4** was obtained by reaction of N-trifluoroacetyl daunomycin with **6** in 40.9% overall yield. Their structures were confirmed by IR, Elemental analysis, ESR and MS. Main spectra data of **2-4** are listed in **Table 1**.

The anticancer activities of compounds **2-4** against mouse leukemia L1210 and human liver cancer BEL-7402 cells *in vitro* were evaluated. The biological activity data

are listed in **Table 2**. As the results shown, they all possessed antitumor activity and compound **4** exhibited comparable activity to **1** in human liver cancer BEL-7402. Further experiments and biological evaluations of these compounds are in progress.

**Table 1** m.p. and spectra data of **2-4**\*

Compd.	m.p.(°C)	IR(KBr,cm <sup>-1</sup> )	MS(APCI, negative)
<b>2</b>	137-139	3422,1716,1654,1617,	694(M+), 380, 347
<b>3</b>	157(dec.)	3348,1715,1652,1617,	836(M+), 380, 365, 347
<b>4</b>	153-155	3450,1725,1717,1630,	790(M+), 410, 380

\*ESR (solid, one line),  $g_0 = 1.997$

**Table 2** IC<sub>50</sub> (µg/mL) of compounds **2-4** and daunomycin **1**

Compd.	<b>2</b>	<b>3</b>	<b>4</b>	<b>1</b>
L1210	>100	78.1	—	23.1
BEL-7402	>100	>100	2.9	1.8

## References

1. L. S. Povarov, O. V. Leonteva, *Bioorg. Khim.*, **1995**, 21(12), 925.
2. B. Elena, *J. Med. Chem.*, **1997**, 40(25), 4013.
3. B. Monica, *Mol. Pharmacol.*, **1997**, 51(6), 1053.
4. S. J. Xu, C. Ma, Y. G. Wang, Y. Z. Chen, *Synth. Commun.*, **2000**, 30(13), 2375.

Received 19 December, 2000